PRPH vs CLOV vs HIMS vs HUM

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Humana Inc. (HUM) offers the better valuation at 25. 1x trailing P/E (27. 7x forward), making it the more compelling value choice. Analysts rate Clover Health Investments, Corp. (CLOV) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Humana Inc.

(HUM) is the cheapest at 25. 1x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Humana Inc. is actually cheaper at 27. 7x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Humana Inc.

(HUM) is the lower-risk stock at 0. 56β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 327% more volatile than HUM relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Humana Inc.

(HUM) trades at 27. 7x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 38. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 18. 1% to $3. 33.

In this comparison, HUM (1.

4% yield) pays a dividend. PRPH, CLOV, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Humana Inc.

(HUM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), 1. 4% yield). ProPhase Labs, Inc. (PRPH) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HUM: +59. 8%, PRPH: +37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRPH is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock. HUM pays a dividend while PRPH, CLOV, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.